HAE

Haemonetics Corporation
$102.69
+1.63 (+1.61%)
Mkt Cap 4.67B
Volume 458,277
52W Range 47.32-109.57
Sector Healthcare
Beta 0.54
EPS (TTM) 2.06 USD
P/E Ratio 49.85
Revenue (TTM) 1.35B USD
Rev Growth (5Y) +5.1%
EPS Growth (5Y) +5.2%
AlphaVal · Fair Value
What we estimate one share is worth
$30.75
Overvalued strong signal
234.0% above fair value
Modeled from cash flows & growth.
AlphaQuality · Grade
How strong & durable the business is
B-
Stable Earnings Power
67.7 / 100 composite
Steady, predictable earnings power — graded A–F vs. similar companies.

Company Description

Track Record

Showing latest 4 periods • Swipe for more
Metric 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Revenue 1.33B 1.36B 1.31B 1.17B 993.20M 870.46M 988.48M 967.58M 903.92M 886.12M 908.83M 910.37M
Net Income 97.31M 167.68M 117.56M 115.40M 43.38M 79.47M 76.53M 55.02M 45.57M (26.27M) (55.62M) 16.90M
EPS 2.05 3.31 2.32 2.27 0.85 1.57 1.51 1.07 0.86 -0.51 -1.09 0.33
Free Cash Flow 260.44M 142.45M 143.63M 162.87M 75.75M 71.77M 109.46M 40.32M 145.55M 83.60M 19.46M 4.96M
FCF / Share 5.52 2.83 2.83 3.21 1.48 1.42 2.16 0.78 2.76 1.62 0.38 0.10
Operating CF 293.22M 181.72M 181.75M 273.06M 172.26M 108.81M 158.22M 159.28M 220.35M 159.74M 121.86M 127.18M
Total Assets 2.40B 2.45B 2.20B 1.93B 1.86B 1.82B 1.27B 1.27B 1.24B 1.24B 1.32B 1.48B
Total Debt 1.22B 1.22B 807.79M 765.89M 780.78M 778.28M 441.81M 350.12M 253.68M 314.65M 408.00M 427.89M
Cash & Equiv 245.44M 306.76M 178.80M 284.47M 259.50M 192.31M 137.31M 169.35M 180.17M 139.56M 115.12M 160.66M
Book Value 796.32M 820.84M 959.96M 818.00M 749.42M 731.67M 587.11M 667.87M 752.43M 739.61M 719.98M 826.12M
Return on Equity 0.12 0.20 0.12 0.14 0.06 0.11 0.13 0.08 0.06 -0.04 -0.08 0.02
HAE News
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug
Sep 09, 2026 07:05 AM · zacks.com
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
Sep 08, 2026 04:00 AM · globenewswire.com
Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks
Sep 08, 2026 02:50 AM · globenewswire.com
GEHC vs. HAE: Which Stock Is the Better Value Option?
Aug 31, 2026 08:41 AM · zacks.com
BioCryst Pharmaceuticals: Owning Both Sides Of The HAE Preference Curve
Aug 28, 2026 07:59 AM · seekingalpha.com
BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan
Aug 25, 2026 03:01 AM · globenewswire.com
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains
Aug 24, 2026 07:01 AM · zacks.com
Haemonetics: Worth Speculating On This Recurring Medtech Plasma Model
Aug 21, 2026 04:30 AM · seekingalpha.com
Aurora Investment Counsel Acquires New Position in Haemonetics Corporation $HAE
Aug 19, 2026 11:48 PM · defenseworld.net
Haemonetics Corp (HAE) Shares Surge 15.9% -- What GF Score of 85 Tells Investors
Aug 18, 2026 03:49 PM · gurufocus.com